中医杂志

参考文献

[1]中华医学会.临床诊疗指南：风湿病分册[M].北京：人民卫生出版社，2005:120.

[2]KUO CF,GRAINGE MJ,ZHANG W,et al.Global epidemiology of gout:prevalence,incidence and risk factors[J].Nat Rev Rheumatol,2015,11(11):649-662.

[3]杨丽华，刘晓丽，蒋雅琼，等.我国痛风的患病率及危险因素[J].医学研究杂志，2019,48(12):4-6,10.

[4]罗卉，方卫纲，左晓霞，等.我国痛风患者临床特点及诊疗现状分析[J].中华内科杂志，2018,57(1):27-31.

[5]KUO CF,GRAINGE MJ,MALLEN C,et al.Comorbidities in patients with gout prior to and following diagnosis:case-control study[J].Ann Rheum Dis,2016,75(1):210-217.

[6]COLANTONIO LD,SAAG KG,SINGH JA,et al.Gout is associated with an increased risk for incident heart failure among older adults:the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study[J].Arthritis Res Ther,2020,22:86.doi:10.1186/s13075-020-02175-2.

[7]BARDIN T,RICHETTE P.Impact of comorbidities on gout and hyperuricaemia:an update on prevalence and treatment options[J].BMC Med,2017,15:123.doi:10.1186/s12916-017-0890-9.

[8]GUYATT GH,OXMAN AD,VIST GE,et al.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ,2008,336(7650):924-926.

[9]JAESCHKE R,GUYATT GH,DELLINGER P,et al.Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive[J].BMJ,2008,337(744):327-330.

[10]中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的实践指南(2017版)[J].中华医学杂志，2017,97(25):1927-1936.

[11]NEOGI T,TLTAJANSEN,DALBETH N,et al.2015Gout classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Ann Rheum Dis,2015,75(2):1789-1798.

[12]WALLACE SL,ROBINSON H,MASI AT,et al.Preliminary criteria for the classification of the acute arthritis of primary gout[J].Arthritis Rheum,1977,20(3):895-900.

[13]张倩茹，王昱，张卓莉.2015 ACR/EULAR痛风分类标准与既往标准诊断价值的比较研究[J].北京大学学报(医学版)，2017,49(6):979-984.

[14]中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.痛风及高尿酸血症基层诊疗指南(2019年)[J].中华全科医师杂志，2020,19(4):293-303.

[15]李滋聪，王川红，曾炳亮，等.双能量CT对别嘌醇片及非布司他治疗痛风石的研究分析[J].江西医药，2019,54(11):1466-1468.

[16]LIU W,WU YH,XUE B,et al.Effect of integrated traditional Chinese and western medicine on gout[J].J Tradit Chin Med,2021,41(5):806-816.

[17]中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志，2020,36(1):1-13.

[18]ZHOU Z,LI K,LI X,et al.Independent and joint associations of body mass index,waist circumference,waistheight ratio and their changes with risks of hyperuricemia in middle-aged and older Chinese individuals:a population-based nationwide cohort study[J].Nutr Metab(Lond),2021,18(1):62.

[19]AUNE D,NORAT T,VATTEN LJ.Body mass index and the risk of gout:a systematic review and doseresponse meta-analysis of prospective studies[J].Eur JNutr,2014,53(8):1591-1601.

[20]MASANARI K,REMI K,KOICHIRO N,et al.Different risk for hypertension,diabetes,dyslipidemia,and hyperuricemia according to level of body mass index in Japanese and American subjects[J].Nutrients,2018,10(8):1011.

[21]CHOI HK,ATKINSON K,KARLSON EW,et al.Obesity,weight change,hypertension,diuretic use,and risk of gout in men:the health professionals follow-up study[J].Arch Inter Med,2005,165(7):742-748.

[22]NIELSEN SM,BARTELS EM,HENRIKSEN M,et al.Weight loss for overweight and obese individuals with gout:a systematic review of longitudinal studies[J].Ann Rheum Dis,2017,76(11):1870-1882.

[23]EBRAHIMPOUR-KOUJAN S,SANEEI P,LARIJANIB,et al.Consumption of sugar-sweetened beverages and serum uric acid concentrations:a systematic review and meta-analysis[J].J Hum Nutr Diet,2021,34(2):305-313.

[24]LIN WT,KAO YH,LIN HY,et al.Age difference in the combined effect of soda drinks consumption and body adiposity on hyperuricaemia in US adults[J].Public Health Nutr,2021,24(17):5756-5768.

[25]MENESES-LEóN J,LEóN-MALDONADO L,MACíASN,et al.Sugar-sweetened beverage consumption and risk of hyperuricemia:a longitudinal analysis of the Health Workers Cohort Study participants in Mexico[J].Am J Clin Nutr,2020,112(3):652-660.

[26]SIQUEIRA JH,MILL JG,VELASQUEZ-MELENDEZG,et al.Sugar-sweetened soft drinks and fructose consumption are associated with hyperuricemia:crosssectional analysis from the Brazilian longitudinal study of adult health (ELSA-Brasil)[J].Nutrients,2018,27,10(8):981.

[27]MURPHY R,THORNLEY S,DE ZOYSA J,et al.Sugar sweetened beverage consumption among adults with gout or type 2 diabetes[J].PLo S One,2015,10(5):e0125543.doi:10.1371/journal.pone.e0125543.

[28]BAE J,CHUN BY,PARK PS,et al.Higher consumption of sugar-sweetened soft drinks increases the risk of hype-ruricemia in Korean population:the Korean MultiRural Communities Cohort Study[J].Semin Arthritis Rheum,2014,43(5):654-661.

[29]GAO X,QI L,QIAO N,et al.Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women[J].Hypertension,2007,50(2):306-312.

[30]WANG M,JIANG X,WU W,et al.A meta-analysis of alcohol consumption and the risk of gout[J].Clin Rheumatol,2013,32(11):1641-1648.

[31]SUGIE T,IMATOU T,MIYAZAKI M,et al.The effect of alcoholic beverage type on hyperuricemia in Japanese male office workers[J].J Epidemiol,2005,15(2):41-47.

[32]CHOI HK,ATKINSON K,KARLSON EW,et al.Alcohol intake and risk of incident gout in men:a prospective study[J].Lancet,2004,363(9417):1277-1281.

[33]辛东岭，刘淑文，戴剑松.不同剂量运动对高尿酸血症影响的试验研究[J].科技资讯，2020,18(13):204-206.

[34]黄叶飞，欧嘉勇，刘琪，等.不同运动频次对高尿酸血症患者痛风发作影响的研究[J].新医学，2018,49(5):355-358.

[35]刘静，武静美.对间歇期原发性痛风患者进行社区饮食护理干预的效果观察[J].当代医药论丛，2019,17(13):270-271.

[36]朱婉华，张爱红，顾冬梅，等.痛风性关节炎中医证候分布规律探讨[J].中医杂志，2012,53(19):1667-1670.

[37]丁宇康，喻建平，莫丽莎，等.痛风性关节炎与湿热浊瘀互结病机相关性的临床研究[J].中国中医药现代远程教育，2020,18(13):73-75.

[38]周苇.平胃散合五苓散治疗高尿酸血症36例[J].浙江中医药大学学报，2007,31(2):182.

[39]梁晖，吴禹池，吴一帆.体质调节法干预治疗气虚夹痰湿体质的高尿酸血症[J].时珍国医国药，2014,25(11):2705-2706.

[40]李萍，王银洁，曹义.四妙散加减对比秋水仙碱治疗痛风疗效和安全性的Meta分析[J].中国中医急症，2019,28(3):449-452.

[41]荣三群，周月红，姜艳，等.加味四妙散治疗湿热蕴结型痛风性关节炎临床观察[J].光明中医，2021,36(12):1975-1977.

[42]FAN Y,LIU W,LU H,et al.Efficacy and safety of Qinpi Tongfeng Formula in the treatment of acute gouty arthritis:a double-blind,double-dummy,multicenter,randomized controlled trial[J].Evid Based Complement Alternat Med,2022:7873426.doi:10.1155/2022/7873426.

[43]刘维，吴沅皞，张磊，等.清热解毒、利湿化浊法治疗痛风的临床随机对照试验[J].中华中医药杂志，2016,31(3):1113-1116.

[44]李雯，戴晓云，柯新桥.当归拈痛汤合宣痹汤加减治疗湿热蕴结型急性痛风性关节炎的临床观察[J].中国实验方剂学杂志，2020,26(14):117-122.

[45]王鹏程，舒建国，花宇琪.当归拈痛汤合宣痹汤治疗急性痛风性关节炎湿热蕴结证75例[J].浙江中医杂志，2021,56(4):274.

[46]罗徐，李芊.新癀片对急性痛风性关节炎患者血清白细胞介素1β和肿瘤坏死因子α的影响研究[J].现代诊断与治疗，2014,25(24):5531-5533.

[47]张明，周敏.新癀片治疗急性痛风性关节炎210例临床观察[J].中国中西医结合杂志，2000,20(3):232.

[48]陈永法，戈颖莹，雷媛，等.新癀片治疗急性痛风性关节炎的成本效果分析[J].中国药物评价，2018,35(1):56-61.

[49]余通，冯芸，张东宁，等.通滞苏润江胶囊治疗痛风性关节炎的Meta分析[J].湖南中医杂志，2019,35(8):120-125.

[50]周俊，肖微，吴锐，等.通滞苏润江胶囊治疗急性痛风性关节炎有效性与安全性的系统评价[J].风湿病与关节炎，2016,5(2):21-27.

[51]赵明久，曹毅，王利，等.四妙丸联合苯溴马隆治疗痛风性关节炎的临床研究[J].现代药物与临床，2019,34(3):820-823.

[52]向珍蛹，邓钰敏，谭海灯.四妙丸联合别嘌醇对痛风性关节炎的疗效[J].河南医学研究，2019,28(14):2628-2630.

[53]刘润萍，刘冬梅，曾芳馨.湿热痹颗粒辅助苯溴马隆片对痛风性关节炎患者血清免疫、炎症指标表达的影响[J].世界中西医结合杂志，2021,16(4):748-752.

[54]韩新峰，杜天信，李无阴.湿热痹颗粒治疗湿热痹阻型风湿病的临床观察[J].中医正骨，2002,14(4):9-11.

[55]张意侗，谢秋芳，梁晖，等.滑膜炎颗粒治疗湿热蕴结型痛风性关节炎的临床研究[J].现代中药研究与实践，2020,34(4):70-73.

[56]张意侗，梁晖，解纪惠，等.滑膜炎颗粒对湿热蕴结型痛风性关节炎血清炎性因子的影响[J].中国医药导报，2020,17(11):153-156.

[57]郭军强.正清风痛宁片联合非布司他治疗痛风性关节炎的作用机制分析[J].临床研究，2019,27(3):118-119.

[58]黄楚泉，林揆斌，丁云岗，等.正清风痛宁片联合非布司他治疗痛风性关节炎的疗效观察及作用机制研究[J].成都医学院学报，2018,13(2):224-227,232.

[59]肖敬，尹智功，陈艺方，等.正清风痛宁治疗湿热蕴结型老年急性痛风性膝关节炎的临床疗效观察[J].湖北中医杂志，2017,39(10):8-11.

[60]林国敬，阮国梅，刘基凤.痛风定胶囊联合苯溴马隆片治疗高尿酸血症的临床研究[J].实用中西医结合临床，2021,21(9):122-123.

[61]段华，邓少清.苯溴马隆与痛风定胶囊联合治疗痛风性关节炎的临床效果分析[J].中国医药科学，2020,10(5):75-77,127.

[62]王倩.别嘌呤醇联合痛风定胶囊对痛风患者炎症因子、肝肾功能及痛风相关指标的影响分析[J].中国现代药物应用，2019,13(12):134-135.

[63]尚秀兰，卢雪红，康英.中西医结合治疗急性痛风60例的临床疗效观察[C]//中国中西医结合学会风湿类疾病专业委员会.第六届中国中西医结合风湿病学术会议论文汇编.北京：中国中西医结合学会，2006:1.

[64]孙维晰，卫四来.当归拈痛丸配合水调散治疗急性期痛风性关节炎51例[J].实用中医内科杂志，2011,25(2):65-66.

[65]欧凡，郭健，刘婷.加味桂枝附子汤联合依托考昔治疗寒湿痹阻型急性痛风性关节炎的疗效[J].中国老年学杂志，2020,40(1):122-125.

[66]吴咏妍，邱联群.桂枝附子汤加味配合外用药治疗寒湿痹阻型痛风性关节炎疗效观察[J].广州中医药大学学报，2019,36(6):796-800.

[67]计康，卢永屹.桂枝芍药知母汤加减治疗寒湿痹阻型痛风急性期患者对其VAS评分、UA、CRP、ESR水平的改善情况[J].医药论坛杂志，2021,42(20):56-59.

[68]包乌吉斯古冷，刘睿，陈爱林.桂枝芍药知母汤加减治疗寒湿痹阻型痛风急性期患者的疗效观察[J].实用临床医药杂志，2020,24(4):57-59.

[69]朱慧敏.桂枝芍药知母汤加味辨治风寒湿痹型急性痛风性关节炎45例[J].河南中医，2019,39(4):508-511.

[70]李晶晶，郝冬林，周腊梅，等.上中下通用痛风方联合美洛昔康治疗急性痛风性关节炎疗效观察[J].现代中西医结合杂志，2021,30(31):3460-3463,3471.

[71]罗正凯，张凤，王金环，等.上中下通用痛风方治疗急性痛风性关节炎35例[J].河南中医，2018,38(9):1381-1383.

[72]沙湖，梁翼，余文景，等.双合汤加减联合非布司他治疗慢性痛风石性关节炎临床观察[J].四川中医，2019,37(5):129-132.

[73]秦克枫，冯素萍，张进川.瘀血痹颗粒治疗瘀血痹阻型风湿病的临床观察[J].中医正骨，2002,14(6):13-15.

[74]王勤志，陈崎，徐立军，等.益肾蠲痹丸内服配合双柏散外敷治疗急性痛风性关节炎疗效观察[J].现代中西医结合杂志，2019,28(16):1781-1784.

[75]万琦兵，杨惠琴.益肾蠲痹丸治疗急性痛风性关节炎30例[J].中医药导报，2012,18(6):96-97.

[76]杨晓凌，刘欢，陈亮，等.防己黄芪汤与非布司他对脾虚湿阻型痛风性关节炎的疗效[J].中国继续医学教育，2018,25(10):142-144.

[77]凌天佑.济生肾气丸合参苓白术散为主治疗痛风性肾痛病34例[J].湖南中医杂志，1999,21(1):26.

[78]顾雪，张莉，孟梅霞，等.黄葵胶囊联合苯溴马隆治疗尿酸性肾病临床研究[J].国际中医中药杂志，2016,38(9):804-807.

[79]张卓君，孙颖，杨晓凌，等.萆薢分清丸联合别嘌醇治疗痛风患者高尿酸血症的临床疗效和安全性[J].复旦学报(医学版)，2020,47(2):245-250.

[80]何健，吴萍，董宇，等.附子不良反应分析及应用网络药理学对其产生心脏毒性的机制预测[J].中国中药杂志，2019,44(5):1010-1018.

[81]李智惠，陈敏，唐纯志.针灸治疗痛风性关节炎预后及安全性的Meta分析[J].中国临床研究，2022,35(2):149-156,166.

[82]张金焕，陈伊镕，兰凯，等.不同针灸疗法治疗急性痛风性关节炎的有效率和对血尿酸及疼痛影响的网状Meta分析[J].中国全科医学，2021,24(8):1001-1010.

[83]张云，甘文渊，刘昌璇，等.刺血疗法治疗痛风性关节炎的Meta分析[J].中医药导报，2018,24(18):115-119.

[84]朱俊发.中药外洗治疗痛风的Meta分析[D].广州：广州中医药大学，2018.

[85]VAN DURME CM,WECHALEKAR MD,LANDEWéRB,et al.Non-steroidal anti-inflammatory drugs for acute gout[J].Cochrane Database Syst Rev,2021,12(12):CD010120.doi:10.1002/14651858.CD010120.

[86]WECHALEKAR MD,VINIK O,MOI JH,et al.The efficacy and safety of treatments for acute gout:results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids,colchicine,nonsteroidal antiinflammatory drugs,and interleukin-1 inhibitors[J].J Rheumatol Suppl,2014,92:15-25.doi:10.3899/jrheum.140458.

[87]FITZGERALD JD,DALBETH N,MIKULS T,et al.2020 American College of Rheumatology Guideline for the Management of Gout[J].Arthritis Care Res(Hoboken),2020,72(6):744-760.

[88]RICHETTE P,DOHERTY M,PASCUAL E,et al.2016 updated EULAR evidence-based recommendations for the management of gout[J].Ann Rheum Dis,2017,76(1):29-42.

[89]KHANNA D,KHANNA PP,FITZGERALD JD,et al.2012 American College of Rheumatology guidelines for management of gout.Part 2:therapy and antiinflammatory prophylaxis of acute gouty arthritis[J].Arthritis Care Res (Hoboken),2012,64(10):1447-1461.

[90]TERKELTAUB RA,FURST DE,BENNETT K,et al.High versus low dosing of oral colchicine for early acute gout flare:twenty-four-hour outcome of the first multicenter,randomized,double-blind,placebo-controlled,parallel-group,dose-comparison colchicine study[J].Arthritis Rheum,2010,62(4):1060-1068.

[91]STAMP LK,CHAPMAN PT,PALMER SC.Allopurinol and kidney function:an update[J].Joint Bone Spine,2016,83(1):19-24.

[92]JUTKOWITZ E,DUBREUIL M,LU N,et al.The costeffectiveness of hla-b*5801 screening to guide initial urate-lowering therapy for gout in the United States[J].Semin Arthritis Rheum,20176,46(5):594-600.

[93]WANG CW,DAO RL,CHUNG WH.Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions[J].Curr Opin Allergy Clin Immunol,2016,16(4):339-345.

[94]BECKER MA,SCHUMACHER HR,ESPINOZA LR,et al.The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout:the CONFIRMS trial[J].Arthritis Res Ther,2010,12(2):R63.doi:10.1186/ar2978.

[95]MüLLER-WIELAND D,NITSCHMANN S.Cardiovascular risk in gout patients:Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES).[J]Internist(Berl),2018,59(11):1224-1228.

[96]HARING B,KUDLICH T,RAUTHE S,et al.Benzbromarone:a double-edged sword that cuts the liver?[J].Eur JGastroenterol Hepatol,2013,25(1):119-121.

[97]YU H,LIU X,SONG Y,et al.Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease:a prospective pilot study[J].Clin Exp Nephrol,2018,22(6):1324-1330.